Vox Sang. 1997;73(2):70-3. Unique Identifier : AIDSLINE /MED97449758
BACKGROUND AND OBJECTIVES: Twenty five to 30% of multiple-transfusion
recipients in India show evidence of infection with both HBV and non-A
non-B hepatitis or HCV. To be licensed, blood banks must screen each
donor unit for HBsAg, antibodies to HIV-1 and -2, and VDRL. MATERIALS
AND METHODS: Between 1989 and 1996, 132,093 voluntary and replacement
donors at this centre were screened for the above markers, using
commercially available kits. Some 19,531 donors were screened for HCV
antibodies in 1995 and 1996 with an in-house EIA, using a synthetic
peptide from core, NS3 and NS4 region proteins of all major HCV strains.
RESULTS: Data were tabulated annually. The proportion of voluntary
donors increased from 15 to 32% during the eight years. HBsAg rates
remained below 2.5%, antibodies to HIV increased from 0.04% to 0.55%,
and VDRL reactivity increased from 0.23 to 0.52% between 1989 and 1995.
Prevalence of all three infections showed a small but significant drop
in 1996, and all three were significantly less frequent in voluntary
donors. HCV antibodies were detected in 1.49% of donors tested. Donors
with multiple infections were uncommon. CONCLUSIONS: A change to
voluntary blood transfusion service and addition of anti-HBc, anti-HCV,
and possibly HIV antigen to the mandatory list for screening donor blood
would reduce posttransfusion infections. Indigenous production of these
assays would mitigate the financial burden, as has been the experience
with the in-house HCV assay.
*Blood Donors *Blood Transfusion/ADVERSE EFFECTS *Virus